Keyword Search
Legend:
CC = Vancouver Convention Centre F = Fairmont Waterfront Vancouver
* = applied session ! = JSM meeting theme
|
Keyword Search Criteria: clinical trial returned 29 record(s)
|
|
Sunday, 07/29/2018
|
Two-Stage Enrichment Clinical Trial Design with Adjustment for Misclassification in Predictive Biomarkers
Yong Lin, Rutgers, The State University of New Jersey; Weichung Joe Shih, Rutgers University; Shou-En Lu, Rutgers University
4:35 PM
|
Real World Evidence Demonstration Projects and Policy Development at FDA
Diqiong Xie, FDA; David Barrett Martin, FDA CDER OMP
4:45 PM
|
Clinical Trial Technologies for Precision Medicine: The Current State of the Art
Steven J Schwager, Medidata Solutions; Ruthanna Davi, Medidata Solutions; Therese Dolan, Medidata Solutions; Jeff Wiser, Medidata Solutions
4:50 PM
|
|
Tuesday, 07/31/2018
|
Patient- and Site-Level Factors Associated with Abstinence Outcome in a Multisite Clinical Trial of a Technology-Delivered Psychosocial Intervention for Substance Use Disorders
Martina Pavlicova, Columbia University; Leila M. Vaezazizi, New York State Psychiatric Institue; Aimee N. C. Campbell, New York State Psychiatric Institute; Mei-Chen Hu, Columbia University; Edward V. Nunes, New York State Psychiatric Institute
|
Clinical Trial Design Comparison with Covariate-Adjusted and Response Adaptive Randomization
Wei Qiao, The University of Texas M.D. Anderson; Xuelin Huang, University of Texas MD Anderson Cancer Center; Jing Ning, The University of Texas M.D. Anderson Cancer Center
|
Endpoint and Time-To-Event Analyzes in Interim Clinical Trial Reports
Scott Diegel, University of Wisconsin-Madison; Ryan Zea, University of Wisconsin-Madison; Melissa Schultz, University of Wisconsin-Madison
|
Clinical Trial Data Transparency and Patient Privacy
Darcy Hille, Merck & Company Inc; T. Ceesay, Merck ; Jonathan Hartzel, Merck
|
Multiple Testing Procedure Consideration in Clinical Trials
Rachael Wen, Sanofi
|
Expected Versus Observed Effects on Conditional Probability for Clinical Trial Futility Assessment
Zhibao Mi, VA CSPCC Perry Point; Kelsey A.L. Alexovitz, VA Cooperative Studies Program Coordinating Center; Xiaoli Lu, VA Cooperative Studies Program Coordinating Center; Kousick Biswas, VA Cooperative Studies Program Coordinating Center; Joseph F Collins, VA Cooperative Studies Program Coordinating Center
|
Desirability Functions for Evaluating Clinical Trial Design Quality
Priscilla K Yen, UCLA; Weng Kee Wong, UCLA
8:50 AM
|
Expected Versus Observed Effects on Conditional Probability for Clinical Trial Futility Assessment
Zhibao Mi, VA CSPCC Perry Point; Kelsey A.L. Alexovitz, VA Cooperative Studies Program Coordinating Center; Xiaoli Lu, VA Cooperative Studies Program Coordinating Center; Kousick Biswas, VA Cooperative Studies Program Coordinating Center; Joseph F Collins, VA Cooperative Studies Program Coordinating Center
8:55 AM
|
Design Considerations in Clinical Trials with Cure Rate Survival Data: a Case Study in Oncology
Grace Liu, Johnson & Johnson; Steven Sun, J&J; Tzu-min Yhe, janssen pharmaceuticals; Tianmeng Lyu, University of Minnesota; Rao Sudhakar, janssen pharmaceuticals; Bruce Xue, Johnson & Johnson China
9:20 AM
|
Multiple Testing Procedure Consideration in Clinical Trials
Rachael Wen, Sanofi
11:30 AM
|
Choosing the Primary Efficacy Analysis for a Randomized Clinical Trial with Competing Risks
Eric Leifer, National Heart, Lung, and Blood Institute; James Troendle, National Institutes of Health; Lauren Kunz, National Heart, Lung, and Blood Institute
2:05 PM
|
Improving the Standards for Reporting of Clinical Trial Data
Jitendra Ganju, Consultant
3:35 PM
|
|
Wednesday, 08/01/2018
|
Practical Guidelines and User-Friendly Software for Bayesian Adaptive Designs
J. Jack Lee, Univ of Texas-M D Anderson Cancer Center
|
Further Extensions of the Two-Stage Randomized Trial Design for Testing Treatment, Self-Selection and Treatment Preference Effects to Include Count Outcomes
Denise Esserman, Yale University; Yu Shi, Yale University
|
A Two-Stage, Phase II Clinical Trial Design with Nested Criteria for Early Stopping and Efficacy: Expected Trial Duration and Tools for Planning
Michelle DeVeaux, Regeneron Pharmaceuticals; Michael John Kane, Yale University; Daniel Zelterman, Yale University
|
Further Extensions of the Two-Stage Randomized Trial Design for Testing Treatment, Self-Selection and Treatment Preference Effects to Include Count Outcomes
Denise Esserman, Yale University; Yu Shi, Yale University
9:20 AM
|
Different Causes of Missing Values in a Randomized Clinical Trial of Kidney Decline: Implications for the Statistical Analysis Plan
Andrzej Galecki, University of Michigan; Cathie Spino, University of Michigan; Alessandro Doria, Joslin Diabetes Center; Michael Mauer, University of Minnesota
9:20 AM
|
A Two-Stage, Phase II Clinical Trial Design with Nested Criteria for Early Stopping and Efficacy: Expected Trial Duration and Tools for Planning
Michelle DeVeaux, Regeneron Pharmaceuticals; Michael John Kane, Yale University; Daniel Zelterman, Yale University
9:50 AM
|
Estimating Probability of Simultaneous Success with Multiple Endpoints Using Truncated Multi-Variate Correlated Normal Distribution
Tianshuang Wu, AbbVie; Yihua Gu, AbbVie; Ziqian Geng, AbbVie; Saurabh Mukhopadhyay, AbbVie
10:50 AM
|
Comparison of Support Vector Machine and Conformal Inference of in Regression Prediction
Kao-Tai Tsai, Celgene
11:20 AM
|
How the ICH E9 Addendum Influenced a Phase III Clinical Trial with a Radiographic Endpoint
Ruvie Martin, Novartis Pharmaceuticals
11:50 AM
|
Real World Data Analysis to Inform Clinical Trial Modeling and Simulation
Zhaoling Meng, sanofi; Dimple Patel, sanofi; Qi Tang, Sanofi; Nadia Gaudel-Dedieu, sanofi; James Rogers, Metrum Research Group
2:45 PM
|
|
|
